Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2025-02-25 AGM Information
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Notice of extraordinary general meeting in Alligator Bioscience AB
AGM Information Classification · 1% confidence The document is explicitly titled "NOTICE OF EXTRAORDINARY GENERAL MEETING IN ALLIGATOR BIOSCIENCE AB". It details the date, time, location, procedures for participation (shareholder registration, proxies), and the proposed agenda items for this meeting. Item 6 on the agenda is a "Resolution on guidelines for remuneration to senior executives," and the document extensively details these proposed guidelines. This content strongly indicates a document prepared for a shareholder meeting, specifically concerning voting on proposals. The closest matching category is AGM-R (AGM Information), as an Extraordinary General Meeting (EGM) follows the same principles as an AGM regarding shareholder voting materials and proposals. While it discusses remuneration (which relates to DEF 14A), the primary purpose and structure of the document is the notice and materials for the meeting itself.
2025-02-25 English
Styrelsen för Alligator Bioscience föreslår en sammanläggning av stamaktier
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Alligator Bioscience announcing a proposal by the Board of Directors to conduct a reverse stock split (sammanläggning av stamaktier) in a 1:1000 ratio. It details the mechanics of the split, the impact on outstanding warrants (TO 12 and TO 13), and the indicative timeline for the process, which requires shareholder approval at an upcoming Extraordinary General Meeting. Since this document describes a change in capital structure (share consolidation) rather than a simple report publication announcement or a general regulatory filing, it falls under the 'Share Issue/Capital Change' category.
2025-02-25 Swedish
The Board of Directors of Alligator Bioscience propose a reverse share split of ordinary shares
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Alligator Bioscience announcing a proposal by the Board of Directors for a reverse share split (1:1,000). It details the mechanics of the split, the impact on share capital, the recalculation of warrants, and provides an indicative timetable for the process. While it mentions an upcoming Extraordinary General Meeting, the document itself is a corporate announcement regarding a change in capital structure (share consolidation). According to the filing definitions, announcements regarding stock splits or capital changes fall under 'Share Issue/Capital Change' (SHA).
2025-02-25 English
Alligator Bioscience’s rights issue is registered - conversion of BTU into shares and warrants
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the registration of a rights issue and the subsequent conversion of BTUs (paid subscribed units) into ordinary shares and warrants. It details the increase in the number of outstanding shares and potential future dilution based on warrant exercise. Crucially, the document explicitly states: 'In accordance with article 2 k of the Prospectus Regulation this press release constitutes an **advertisement**.' Furthermore, it mentions that the Prospectus was published previously on January 24, 2025, and this release is not the prospectus itself. Since the core subject is a capital/financing activity (Rights Issue, share conversion, dilution) and it is presented as an announcement/advertisement rather than a comprehensive report or a simple notice of publication, the most fitting category is 'Capital/Financing Update' (CAP). It is not a general Regulatory Filing (RNS) because it fits the specific CAP definition well, and it is not an RPA because it is providing substantive details about the financing event, not just announcing the release of a separate, attached report.
2025-02-24 English
Alligator Biosciences företrädesemission är registrerad – omvandling av BTU till aktier och teckningsoptioner
Capital/Financing Update Classification · 1% confidence The document is a press release from Alligator Bioscience AB announcing that its rights issue ('företrädesemission') has been registered with the Swedish Companies Registration Office ('Bolagsverket'). It details the conversion of BTU (Paid Subscribed Units) into shares and warrants, and provides extensive information on the resulting increase in the total number of outstanding shares and potential dilution effects. This content relates directly to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it is a press release, the core subject matter is the completion of a financing event, making CAP more specific than a general RPA or RNS.
2025-02-24 Swedish
Alligator Bioscience genomför en riktad emission av units till garanter samt en riktad emission av teckningsoptioner till Fenja Capital i samband med den genomförda företrädesemissionen
Capital/Financing Update Classification · 1% confidence The document is a press release from Alligator Bioscience AB detailing two key corporate actions: 1) A directed issue of units to guarantors as compensation for underwriting services related to a previous rights issue ('Ersättningsemissionen'). 2) A directed issue of warrants to Fenja Capital as part of a loan restructuring ('Nya Lånet'). The text explicitly discusses the issuance of shares (units) and warrants, the resulting capital structure changes, dilution, and the rationale for bypassing shareholder pre-emption rights. This content directly relates to capital structure changes and fundraising activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it contains the substantive details of the financing transaction itself.
2025-02-20 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.